Clinical trial NCT00758264: Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration
Official title: Immunogenicity & Safety Study of GSK Biologicals' Meningococcal Vaccine GSK134612 When Co-administered With GSK Biologicals' Pneumococcal Vaccine GSK1024850A in Healthy 12-23-month-old Children Previously Primed With GSK1024850A
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Infections, Meningococcal
Keywords: Safety
Routine infancy vaccination
Meningococcal vaccine
Immunogenicity
Pneumococcal vaccine
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2008-09-25
Enrollment: 363
Sex: ALL
Minimum age (years): 12
Maximum age (years): 23
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to demonstrate, in 12-23 months old subjects, the non-inferiority of meningococcal vaccine GSK134612 and pneumococcal vaccine GSK1024850A when co-administered, compared to each vaccine administered individually.

Detailed description: Multi-center study with 3 parallel groups. One group will receive 2 vaccines injections at the same visit (pneumococcal+ meningococcal), one group will receive a pneumococcal vaccine followed one month later by a meningococcal vaccine, and the last group will receive the meningococcal vaccine followed one month later by the pneumococcal vaccine.

All subjects will have one blood sample taken before vaccination and one blood sample taken one month after each vaccination (i.e. the first group will have 2 blood samples taken, and the other two groups will have 3 blood sample taken)

Eligibility criteria: Inclusion Criteria:

* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.
* A male or female between, and including, 12 and 23 months of age at the time of the first booster vaccination, who previously participated in study 109661 conducted in Mexico or in study 109861 conducted in Taiwan and who received 3 doses of the GSK1024850A vaccine.
* Written informed consent obtained from the parent or guardian of the subject.
* Healthy subjects as established by medical history and clinical examination before entering into the study.

Exclusion Criteria:

* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccine(s), or planned use during the study period.
* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
* Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days before the first dose of vaccine(s) and 30 days after the last dose of vaccine(s).
* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
* Previous vaccination with a meningococcal vaccine.
* Previous administration of a fourth dose of a pneumococcal vaccine
* Previous vaccination with tetanus toxoid within the last month (including also tetanus toxoid given as part of Hib-TT conjugate vaccine).
* History of meningococcal or pneumococcal invasive disease.
* History of reactions or allergic disease likely to be exacerbated by any component of the vaccines.
* Hypersensitivity reaction due to previous vaccination with GSK1024850A vaccine.
* History of seizures (this criterion does not apply to subjects who have had a single, uncomplicated febrile convulsion in the past) or progressive neurological disease.
* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection, based on medical history and physical examination (no laboratory testing required).
* A family history of congenital or hereditary immunodeficiency, unless the child has previously been documented, through laboratory testing, to have normal immune function.
* Major congenital defects or serious chronic illness.
* Acute disease at the time of enrolment.
* Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.

Primary outcomes:
measure: Anti-pneumococcal Antibody Concentrations
timeFrame: At Month 1
measure: Number of Subjects With Serum Bactericidal Assay Using Rabbit Complement Against Neisseria Meningitides Serogroups A, C , W-135, Y (rSBA-MenA, rSBA-MenC, rSBA-MenW -135 and rSBA-Men-Y) Antibody Titers Greater Than or Equal to (≥) the Cut-off Value
timeFrame: At Month 1
measure: rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-Men-Y Antibody Titers
timeFrame: At Month 1
Secondary outcomes:
measure: Anti-pneumococcal Antibody Concentrations
timeFrame: Before vaccination (PRE) and at one month post dose 2 (Month 2)
measure: Cross-reactive Anti-pneumococcal Antibody Concentrations
timeFrame: Before vaccination (PRE), at one month post dose 1 (Month 1) and at one month post dose 2 (Month 2)
measure: Opsonophagocytic Titers Against Pneumococcal Serotypes
timeFrame: Before vaccination (PRE), at one month post dose 1 (Month 1) and at one month post dose 2 (Month 2)
measure: Opsonophagocytic Titers Against Cross-reactive Pneumococcal Serotypes
timeFrame: Before vaccination (PRE), at one month post dose 1 (Month 1) and at one month post dose 2 (Month 2)
measure: Anti-protein D (Anti-PD) Antibody Concentrations
timeFrame: Before vaccination (PRE), at one month post dose 1(Month 1) and at one month post dose 2 (Month 2)
measure: rSBA-MenA, rSBA-MenC, rSBA-MenW -135 and rSBA-Men-Y Antibody Titers
timeFrame: Before vaccination (PRE) and at one month post dose 2 (Month 2)
measure: Anti-meningococcal Polysaccharide (Anti-PS) Antibody Concentrations
timeFrame: Before vaccination (PRE), at one month post dose 1 (Month 1) and at one month post dose 2 (Month 2)
measure: Anti-tetanus (Anti-T) Antibody Concentrations
timeFrame: Before vaccination (PRE), at one month post dose 1 (Month 1) and at one month post dose 2 (Month 2)
measure: Number of Subjects With Any and Grade 3 Solicited Local Symptoms
timeFrame: Within the 4-day (Days 0-3) post-vaccination period after each dose
measure: Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
timeFrame: Within the 4-day (Days 0-3) post-vaccination period after each dose
measure: Number of Subjects With Any Unsolicited Adverse Events (AEs)
timeFrame: Within the 31-day (Day 0-30) post-vaccination period after each dose
measure: Number of Subjects With Serious Adverse Events (SAEs)
timeFrame: Throughout the entire study duration (Day 0-Month 7)
measure: Number of Subjects Reporting Rash
timeFrame: Throughout the entire study duration (Day 0-Month 7)
measure: Number of Subjects With New Onset Chronic Illnesses (NOCIs)
timeFrame: Throughout the entire study duration (Day 0-Month 7)
measure: Number of Subjects Reporting Adverse Events Resulting in Emergency Room (ER) Visits
timeFrame: Throughout the entire study duration (Day 0-Month 7)
Other outcomes:
Locations:
city: Mexico city
country: Mexico
facility: GSK Investigational Site
city: Mexico
country: Mexico
facility: GSK Investigational Site
city: Taipei
country: Taiwan
facility: GSK Investigational Site
city: Taipei
country: Taiwan
facility: GSK Investigational Site
city: Taoyuan Hsien
country: Taiwan
facility: GSK Investigational Site
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References:
citation: Huang LM et al. Immunogenicity and safety of PHiD-CV coadministered with a candidate meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in children previously primed with PHiD. Abstract presented at the 5th Asian Congress of Pediatric Infectious Diseases (ACPID). Taipei, Taiwan, 23-26 September 2010.
citation: Ruiz-Palacios GM, Huang LM, Lin TY, Hernandez L, Guerrero ML, Villalobos AL, Van der Wielen M, Moreira M, Fissette L, Borys D, Miller JM. Immunogenicity and safety of a booster dose of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine coadministered with the tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers: a randomized trial. Pediatr Infect Dis J. 2013 Jan;32(1):62-71. doi: 10.1097/INF.0b013e3182784143.